Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis

References

• Acorda. Ampyra (dalfampridine) extended release tablets prescribing information. Hawthorne, NY: Acorda Therapeutics Inc., January 2011
   Google Scholar
• Australian Public Assessment Report for Fampridine. Australian Government. Woden, Canberra, Australia: Australian Government, Department of Health and Aging, Therapeutic Goods Administration, June 2011. Available at: http://www.tga.gov.au/pdf/auspar/auspar-fampyra.pdf [Last accessed 11 January 2012]
   Google Scholar
• Summary of opinion (initial authorisation) for Fampyra (fampridine). European Medicines Agency Committee. London, United Kingdom: European Medicines Agency Committee for Medicinal Products for Human Use, 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002097/WC500106531.pdf [Last accessed 11 January 2012]
   Google Scholar
• Bowman WC, Savage AO. Pharmacological actions of aminopyridines and related compounds. Rev Pure Appl Pharmacol Sci 1981;2:317-71
   PubMedGoogle Scholar
• Gold MS, Shuster MJ, Levine JD. Characterization of six voltage-gated K+ currents in adult rat sensory neurons. J Neurophysiol 1996;75:2629-46
   PubMed Web of Science ®Google Scholar
• Coetzee WA, Amarillo Y, Chiu J, et al. Molecular diversity of K+ channels. Ann N Y Acad Sci 1999;868:233-85
   PubMed Web of Science ®Google Scholar
• Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:570-2
   PubMed Web of Science ®Google Scholar
• Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-61
   PubMed Web of Science ®Google Scholar
• Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989;22:47-52
   PubMed Web of Science ®Google Scholar
• Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77:553-62
   PubMed Web of Science ®Google Scholar
• Stefoski D, Davis FA, Faut M, et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-7
   PubMed Web of Science ®Google Scholar
• Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-92
   PubMed Web of Science ®Google Scholar
• Van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:123-30
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44:1054-9
   PubMed Web of Science ®Google Scholar
• Hayes KC, Katz MA, Devane JG, et al. Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;43:379-85
   PubMed Web of Science ®Google Scholar
• Uges DR, Sohn YJ, Greijdanus B, et al. 4-Aminopyridine kinetics. Clin Pharmacol Ther 1982;31:587-93
   PubMed Web of Science ®Google Scholar
• Blight AR, Henney HR 3rd. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009;31:328-35
   PubMed Web of Science ®Google Scholar
• Vollmer T, Henney HR 3rd. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I–II, open-label trial. Clin Ther 2009;31:2206-14
   PubMed Web of Science ®Google Scholar
• Vollmer T, Blight AR, Henney HR 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther 2009;31:2215-23
   PubMed Web of Science ®Google Scholar
• Smith W, Swan S, Marbury T, et al. Single-dose pharmacokinetics of sustained-release fampridine (fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50:151-9
   PubMed Web of Science ®Google Scholar
• Acorda Therapeutics. Data on file. Protocol FeFa25F-SR1120. A single dose, two-way crossover, bioequivalence study of fampridine-SR with and without food when administered to healthy adult volunteers. MDS Pharma Services Project AA06715. Hawthorne, NY: Acorda Therapeutics Inc., March 2004
   Google Scholar
• Acorda Therapeutics. Data on file. Protocol 0195-001US. Pharmacokinetic and tolerability evaluation of single dose fampridine SR tablets under fed and fasted conditions, single dose fampridine SR capsules under fasted conditions, and multiple dose fampridine SR tablets in patients with multiple sclerosis [tolerability evaluation]. Final report. Hawthorne, NY: Acorda Therapeutics Inc., May 1996
   Google Scholar
• Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp LB, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502
   PubMed Web of Science ®Google Scholar
• Guidance for industry. Population pharmacokinetics. Food and Drug Administration (FDA). Rockville, MD: FDA/Center for Drug Evaluation and Research, 1999. Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf [Last accessed 9 May 2012]
   Google Scholar
• Ben-Zacharia AB. Therapeutics for multiple sclerosis symptoms. Mt Sinai J Med 2011;78:176-91
   PubMed Web of Science ®Google Scholar
• Henney HR 3rd, Faust B, Blight AR. Effect of food on the single-dose pharmacokinetics of dalfampridine extended release tablets in healthy volunteers. Am J Health Syst Pharm 2011;68:2148-54
   PubMed Web of Science ®Google Scholar
• Brown T, Schapiro R, Edwards K, et al. Response to treatment with dalfampridine extended release tablets in patients with multiple sclerosis is independent of baseline patient characteristics and concomitant immunomodulator therapy. [Abstract.] Neurology 2010;74(Suppl 2):A543
   Google Scholar
• Schapiro R, Brown T, Goodman A, et al. Doses of dalfampridine extended release tablets greater than 10 mg twice daily are associated with increased adverse events but not increased efficacy. [Abstract.] Neurology 2011;76(Suppl 4):A245
   Google Scholar